What we do
We progress promising early-stage science for some of the most under-served health conditions by funding it, forming partnerships, and providing scientific and commercialisation support.
Funding
Find details of open funding calls, including eligibility criteria.
Scientific support
Drug discovery, antibody humanisation and discovery and diagnostics development through our labs.
Commercialisation and IP protection
Technology transfer services and expert advice to protect and bring your research to market.
Investment in early ventures
Seed and series A investments, plus significant scientific support and follow-on investment.
Interested in partnering with us?
Many times, we assist a partner with a combination of the areas described above. We’ll start with a conversation and go from there.
Policy and public affairs
We talk to decision-makers across the political spectrum who influence the way research and innovation happen in the UK.
By feeding in our expertise and collaborating with others, we can build a better system in the UK for speeding good science out of the lab and into real-life, closer to the people who really need it.
Latest news
-
LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases
Read more: LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases -
First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases
Read more: First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases -
New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya
Read more: New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya